Researchers studying lung cancer draw on more than 800 cell lines as a scientific baseline. Not one of them came from a Hispanic/Latin(x), American Indian/Alaska Native, or Native Hawaiian/Pacific Islander patient, and only about 3% are from Black patients. Eugene Manley Jr., PhD is a biomedical research scientist, mechanical engineer, patient advocate, and the Founder and CEO of the STEMM & Cancer Health Equity (SCHEQ) Foundation in New York City. Before founding SCHEQ, he served as Director of STEM Workforce Initiatives at LUNGevity. He also co-authored the review in Frontiers in Oncology that uncovered the patient mix and cataloged the lung cancer cell lines available to researchers worldwide.In this episode, he and host Samira Daswani trace a problem most conversations about clinical trial diversity never reach. The underrepresentation does not begin at enrollment. It begins upstream, in the cell lines, reference genomes, and funding decisions that shape what science gets done at all.Dr. Manley’s review found 390 lung cancer cell lines from Asian patients and nearly 200 from White patients, but only 31 from Black patients and none at all from three other groups. When the input material is not representative, no amount of downstream clinical trial recruitment can fix it.The conversation covers:Why cell lines and reference genomes are the real starting point for drug developmentWhat the 2023 Frontiers in Oncology review found, and what it means for who a drug is designed to work onHow funding decisions shape which questions researchers can even askWhy patients enroll in trials at much higher rates when someone simply asksWhat to request at diagnosis, including biomarker testing, ideally NGS, and a patient or nurse navigatorHow to read your own chart, advocate for accuracy, and document discrepancies while you are still in the hospitalWhat Dr. Manley learned about advocating for himself while on MedicaidCHAPTERS00:00 The bias does not start at the clinical trial00:23 Meet Dr. Eugene Manley Jr., PhD01:15 Detroit roots, chronic asthma, and the road into science02:31 Why a bench scientist became a patient advocate03:26 Experiencing medical racism as a patient05:24 Finding your voice when the system is not listening07:08 "Alert and oriented": how three words shape your care08:10 Bring a proxy and read your chart in real time10:47 When the chart becomes fact: correcting your record11:20 Why oncology trials still are not representative12:46 It is not the trial, it is the whole system13:13 The cell line gap: what the lab starts with14:39 Where the bias actually begins: basic science15:44 Breast cancer outcomes: biology, not just zip code16:28 Reference genomes and databases skew European17:10 Why he founded the SCHEQ Foundation20:02 Newly diagnosed: biomarker testing and navigation21:19 When a clinical trial should be offered to you22:56 How to start the trial conversation with your team23:53 Inside the SCHEQ Foundation's work25:18 Closing thoughtsDr. Eugene Manley, Jr., PhD, MS, is a biomedical scientist-turned-social impact leader and Founder & CEO of the STEMM & Cancer Health Equity (SCHEQ) Foundation. With more than 20 years of experience spanning molecular biology, cancer research, nonprofit strategy, workforce development, and health equity, he has held leadership roles with organizations including AACR, LCRF, and LUNGevity Foundation. Through SCHEQ, Dr. Manley advances STEMM workforce diversity and patient-centered cancer solutions, with a focus on improving access to screening, biomarker testing, clinical trials, and survivorship resources for underserved communities.🔗 Connect with Patient From HellWebsite: https://www.mantacares.comDisclaimerThis podcast is intended for educational and informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding diagnosis, treatment, or medical decisions.

This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From antibody drug conjugates and small molecules to cell therapy-based approaches, our portfolio and pipeline assets are creating new possibilities for people with cancer.Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, returns to Patient From Hell to explain the ASCENT-04/KEYNOTE-D19 study, the phase 3 trial she led as principal investigator, and what it changes for people living with metastatic triple-negative breast cancer.For years, the most effective drugs for metastatic TNBC were only available after first-line chemotherapy had already failed. The problem, as Dr. Tolaney puts it plainly, is that many patients never reach a second line of treatment at all. ASCENT-04 asked whether moving an antibody-drug conjugate to the front, paired with immunotherapy, would change that. Median progression-free survival improved from 7.8 months to 11.2 months, and treatment responses lasted significantly longer.UPDATE: Since this recorded conversation, the FDA has acted on the data discussed in this episode. On May 22, 2026, Datopotamab Deruxtecan was approved for first-line metastatic TNBC in patients who are not candidates for immunotherapy. On June 24, 2026, Sacituzumab Govitecan was approved for first-line use both as a single agent and in combination with pembrolizumab for PD-L1-positive disease (CPS ≥10). Consult with your care team for the most recent indications and availability of these treatment options.00:00 The trial that moves the best drugs first 00:31 Welcome back, Dr. Sara Tolaney 00:40 What ASCENT-04 set out to solve 02:00 Why many patients never reach second-line treatment 02:50 What PD-L1 status means for your treatment 04:12 The result: 7.8 to 11.2 months 05:29 What is an antibody-drug conjugate (ADC)? 06:33 Why TROP-2 is the target in triple-negative breast cancer 07:24 How immunotherapy works: taking the brakes off the T cell 09:01 Who was eligible for the trial 10:05 What "controlling" cancer actually means 11:44 Progression-free survival vs. duration of response 13:37 Dr. Tolaney reconsiders: what ASCENT-03 showed 15:51 How trial data reaches your oncologist's office 18:21 The testing checklist after a metastatic diagnosis 19:59 First-line treatment options today 22:27 The new paradigm: ADCs as the first-line backbone 23:51 What comes second line 25:29 Why tumor sequencing matters: somatic BRCA, TMB, trials 27:24 Twenty years of change in triple-negative breast cancer 29:28 Advice for a newly diagnosed patientSara M. Tolaney, MD, MPH is Chief of the Division of Breast Oncology and Associate Director of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. She trained at Princeton University, UC San Francisco, Johns Hopkins University, and Dana-Farber Cancer Institute, and holds a Masters in Public Health (MPH) from Harvard University. She serves on the National Cancer Institute (NCI) Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer for the Alliance for Clinical Trials in Oncology. She was principal investigator of ASCENT-04.🔗 Connect with Patient From HellWebsite: https://www.mantacares.comDisclaimerThis podcast is intended for educational and informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding diagnosis, treatment, or medical decisions.

Shira Boehler's family is full of doctors, and every one of them told her not to get the full-body MRI. She canceled the appointment repeatedly herself, until her husband rebooked it one time too many and she finally went.The scan found a 3.8 centimeter mass in her right lung and labeled it a minor finding, with a note to correlate with symptoms. She had none. She was running six miles a day, the picture of health, and had never smoked. A follow-up CT months later showed the mass had grown, and on the Monday she walked into a pulmonary specialist's office she was told she had an invasive adenocarcinoma. She told him it was probably an EMR error. One week later, surgeons removed half her right lung to treat her cancer.Samira Daswani, host of Patient from Hell and founder of Manta Cares, welcomes lung cancer survivor and bestselling author Shira Boehler for an eye-opening conversation on the part that comes after the story, which is why almost nobody in Shira's position gets caught this early. Screening guidelines currently cover people over 50 with a twenty-pack-per-year smoking history, and fewer than one in five of them actually get scanned, in part because the criteria require disclosing something patients are ashamed of. Shira has been working the problem from both ends since her treatment, negotiating cash prices at imaging centers down to a fraction of what she paid and funding new scans for people who can't cover them through the nonprofit organization she founded, Cancer Doesn't Care.In this episode, Samira and Shira discuss:Why lung cancer is often diagnosed too lateThe importance of early detection and low-dose CT screeningHow people who have never smoked can still develop lung cancerThe stigma surrounding lung cancer diagnosisCurrent lung cancer screening guidelinesInsurance coverage, healthcare access, policy reformHow artificial intelligence may improve cancer screeningWhy patient advocacy is becoming increasingly important in modern healthcareChapters00:00 Introduction01:00 The Full-Body Scan That Changed Everything03:32 Diagnosed With Lung Cancer Despite Having No Symptoms05:30 Access, Privilege & Why Early Detection Isn't Equal07:10 Building the Cancer Doesn't Care Foundation09:21 Why Lung Cancer Screening Needs to Change10:19 Breaking the Stigma Around Lung Cancer12:26 Who Actually Qualifies for Screening?14:23 Changing Public Perception Through Advocacy16:20 Why Patients Must Advocate for Themselves17:15 AI, False Positives & the Future of Cancer Screening20:27 Why Lung Cancer Is Often Diagnosed Too Late21:17 Stage 1 vs. Stage 4 Survival Rates23:25 Shira's Advice for Anyone Considering Lung Cancer ScreeningShira Kupperman Boehler is a finance professional, health advocate, bestselling author, and lung cancer survivor. Shira holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University’s Stern School of Business. Alongside her husband Adam, she has spent her career building and scaling multibillion-dollar healthcare businesses, developing deep relationships across health systems, payers, and policymakers.After being unexpectedly diagnosed with Stage 1B lung adenocarcinoma despite never smoking and having no symptoms, Shira founded Cancer Doesn't Care, a nonprofit dedicated to expanding access to life-saving lung cancer screening and reducing financial barriers to early detection. She is also the author of the bestselling memoir One Scan Saved My Life, with proceeds supporting patient screening initiatives.🔗 Connect with Patient From HellWebsite: https://www.mantacares.comDisclaimerThis podcast is intended for educational and informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding diagnosis, treatment, or medical decisions.

This episode is dedicated to Natalie's memory and to every patient navigating life with cancer.Natalie Brown's answer to "How are you?" was always simple:"I'm here."Diagnosed with stage 4 non-small cell lung cancer at just 33 years old, despite never smoking and having no family history of lung cancer, Natalie spent six years challenging assumptions about what lung cancer looks like.In this unforgettable conversation with host Samira Daswani, Natalie shares her journey through multiple rounds of chemotherapy, immunotherapy, failed clinical trials, and one of the rarest procedures in cancer medicine a bilateral double lung transplant. She also opens up about recurrence, chronic pain, advocacy, mental health, and why she believed every patient deserves to know all of their treatment options.Natalie has passed away. We are honored to share her story again in celebration of the courage, honesty, humor, and determination that defined her life. Her voice continues to educate, inspire, and advocate for patients everywhere.Whether you're living with cancer, supporting someone who is, or simply want to better understand the realities of serious illness, Natalie's message is one everyone should hear.In this episode you'll learn:What it's like to be diagnosed with stage 4 lung cancer at age 33Why non-smokers can develop lung cancerHow a rare double lung transplant became a treatment optionThe emotional reality of cancer recurrenceClinical trials, targeted therapies, and asking "What's next?"The importance of patient advocacy and second opinionsHow friends, family, therapy, and hope helped Natalie keep fightingWhy "Anyone with lungs can get lung cancer"Natalie's story reminds us that resilience isn't about pretending things aren't difficult—it's about continuing to move forward anyway.00:00 Introduction: Remembering Natalie Brown01:00 "I'm Here" — The phrase that defined Natalie02:00 Diagnosed with Stage 4 Lung Cancer at 3304:00 Four Chemotherapies & Failed Clinical Trials05:30 Discovering a Rare Double Lung Transplant10:40 Returning Home After Transplant11:45 Cancer Recurrence & New Treatment Options13:00 The Husband Who Helped Her Keep Fighting16:00 Facing Mortality with Honesty18:00 Making the Most of Time20:00 Living with Chronic Pain21:00 Becoming a Lung Cancer Advocate24:00 Learning to Ask for Help26:45 Advice for Newly Diagnosed Patients28:40 "Anyone With Lungs Can Get Lung Cancer"29:45 Why Patients Should Always Ask Questions31:00 Final ReflectionsAbout Patient From HellPatient From Hell is hosted by cancer survivor and founder Samira Daswani, who asks the questions most patients are too overwhelmed or too afraid to ask. The show brings together doctors, researchers, advocates, and survivors to reveal evidence-based answers for patients navigating the chaos of cancer.🔔 Connect & FollowSamira DaswaniLinkedIn: https://www.linkedin.com/in/samiradaswani/ Manta Cares: https://www.mantacares.comDisclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions.

Tim McDonald was sitting down for Thanksgiving dinner in 2020 when the pain started. A few days later, a doctor handed him a single sheet of paper and said three words nobody wants to hear: "You have cancer."Stage 4 colorectal cancer. Liver covered in tumors. A second oncologist told him he had three years to live and she'd focus on "quality of life." His response? "That's your story. Not mine."In this episode, Tim shares how over a decade of mindfulness practice shaped the way he faced one of the hardest diagnoses a person can receive and how he went from following doctors' orders to becoming the general manager of his own care team, ultimately pursuing a liver transplant at a time when fewer than 20 people in the US had received one for colorectal cancer.This conversation goes deep on:→ What it actually feels like to hear "you have cancer" and stay calm→ Why getting a second (and third, and tenth) opinion saved his life→ The player → quarterback → general manager framework for owning your treatment→ Men, vulnerability, and why cancer support groups changed everything→ The dark thought he had toward the end of chemo — and what pulled him back→ Why survivorship was mentally harder than treatment itself→ How advocacy work became part of his healingIf you or someone you love is navigating a cancer diagnosis, this episode is essential listening.───────────────────────────🔔 Subscribe for weekly conversations with patients, advocates, and caregivers navigating the healthcare system.───────────────────────────CHAPTERS00:00 – The mindset that got him through00:29 – Meet Tim McDonald01:17 – Thanksgiving diagnosis02:44 – Hearing "you have cancer" — and staying calm04:51 – Life before cancer: HuffPost, Arianna Huffington, and mindfulness06:04 – What mindfulness actually gave him during treatment07:14 – Starting standard treatment and meeting a new oncologist09:38 – "That's your story. Not mine."10:20 – Switching to Moffitt Cancer Center11:53 – Discovering the liver transplant option13:22 – Stage 4 colorectal cancer explained17:49 – Going from patient to general manager of your care team21:26 – The proctologist nobody thought to send him to23:21 – Why you should always get a second opinion24:46 – Men and cancer: processing emotions differently26:18 – Vulnerability and who to open up to29:02 – The dark thought: wanting to stop treatment entirely30:52 – What pulled him back from the edge31:39 – Survivorship: why after treatment can be harder34:11 – 10 doctors after, 3 before: the survivorship reality───────────────────────────GUESTTim McDonald: Stage 4 colorectal cancer survivor, liver transplant recipient, patient advocate, and community builder. Former Director of Community at HuffPost.───────────────────────────ABOUT THE PATIENT FROM HELLPatient From Hell is a podcast about navigating the healthcare system with confidence, curiosity, and zero apologies. Hosted by Samira Daswani, CEO and founder of Manta Cares.#CancerSurvivor #ColorectalCancer #PatientAdvocacy #Stagefour #LiverTransplant #CancerMindset #ChemoSideEffects #PatientFromHell #MantaCares #CancerPodcast

When Marybeth Gilliam was diagnosed with metastatic breast cancer, she did what her years as a healthcare researcher had trained her to do: she went looking for the evidence. What she found was a gap between a growing body of peer-reviewed research pointing to strategies that can improve outcomes, and the fact that most of it never reached patients because it hadn't yet become standard of care.In this episode of Patient From Hell, host Samira Daswani sits down with Marybeth, founder of Outperform Cancer, to talk about how she is working to close that gap. She translates overlooked, peer-reviewed findings into steps patients can actually take, always paired with standard treatment rather than in place of it. Exercise, nutrition, and sleep are part of it, and so is asking sharper questions about biomarker testing, weighing well-supported off-label options, and refusing to take no for an answer when the data is strong.She shares her own story, the research that reshaped her thinking, and a practical case for taking an active role in your care when the first treatment decisions matter most.In this episode:Why she founded Outperform Cancer to close the gap between research and the clinicHow she pairs evidence-based strategies with standard treatment, not instead of itBiomarker testing and advocating for off-label options backed by solid trials (PATINA, MA.32)What being your own advocate actually looks like in the exam roomThis podcast is for general informational purposes only and does not constitute medical advice. The opinions of the speakers are their own.CHAPTERS00:00 The overlooked risk factor after childbirth00:39 Meet Marybeth Gilliam00:53 Why she founded Outperform Cancer02:15 The cancer care information gap02:20 The exercise discovery that changed everything04:14 Her metastatic breast cancer diagnosis06:11 Looking back at her 2007 Stage 0 diagnosis07:16 Postpartum breast cancer and recurrence risk10:36 Building an anti-cancer strategy13:58 From metastatic diagnosis to NED15:48 Exercise, sleep, nutrition, and lifestyle changes18:24 Creating an anti-cancer environment20:03 The PATINA trial explained23:24 Accessing promising therapies before standard of care25:46 How patients can advocate for themselves27:51 The 15-year research-to-practice gap28:45 Precision medicine and biomarker testing30:42 The ATM gene and metformin research32:08 Stacking interventions: what does the evidence say?33:08 Balancing risk, reward, and patient choice35:24 Lessons from cancer innovators and patient-led research37:00 Final thoughts and takeawaysFollow Patient From Hell for more conversations on cancer, survivorship, patient advocacy, research breakthroughs, and navigating healthcare with confidence.Understanding postpartum breast cancer risks is critical. Learn why a diagnosis within 10 years of childbirth changes prognosis.Many patients do not realize that postpartum breast cancer is defined as a diagnosis within 10 years of having children. This video explains the medical reasoning behind why these patients face a significantly higher likelihood of recurrence compared to other groups. We specifically look at the data showing that even stage one patients are three times more prone to metastasis during this specific window.

Welcome to the Patient from Hell podcast! Live from ASCO 2026, we explore breakthroughs in clinical oncology, cancer research, AI healthcare tools, and targeted therapy for advanced cancer.Samira Daswani, Founder and CEO of Manta Cares and host of The Patient From Hell, sits down with Dr. Doug Blayney, Chief Medical Officer of Manta Cares and former ASCO President, for a candid debrief in between sessions at the 2026 ASCO Annual Meeting in Chicago.With 45,000 oncology professionals in attendance, ASCO is the largest gathering of cancer researchers and clinicians in the world. In this episode, Samira and Dr. Blayney break down what actually mattered: the clinical findings, the shifting treatment landscape, and what the research trends mean for patients navigating cancer today.This episode is for oncologists, cancer researchers, and anyone who wants to understand where the field is heading.Topics covered, with more to come in our next episode:Key clinical findings from ASCO 2026Trends shaping experimental and clinical oncologyWhat high attendance and collaboration signals for the future of cancer researchWhat patients should know coming out of this year's conferenceCHAPTERS:0:00 - ASCO 2026 Annual Meeting Live from Chicago0:27 - Artificial Intelligence (AI) in Oncology & Patient Experience1:19 - Healthcare AI Challenges: Misinformation & Clinician Deskilling2:03 - Pancreatic Cancer Breakthrough: New RAS/KRAS Targeted Therapy2:30 - Lung Cancer Advancements: ALK Mutations & PD-L1 Data3:01 - Breast Cancer Innovation: Oral SERDs & ESR1 Biomarkers3:41 - Next Episode Preview & Wrap UpSubscribe for frequent breakdowns of cancer research, treatment news, patient stories, and guidance and support for people in treatment for cancer. Drop a comment with the topics or trials you want us to cover next!

What happens when a medical doctor trained in oncology becomes the cancer patient and then transforms into a primary caregiver for his own father? In this moving continuation of our conversation with clinician, survivor, and care partner Dr. Achim, we dive into the profound emotional architecture of navigating a cancer diagnosis. Dr. Achim opens up about the vast difference between his first experience as a helpless care partner for his father’s prostate cancer in 2010, and his recent role guiding his 85-year-old father through aggressive lymphoma and groundbreaking CAR T-cell therapy.Samira and Dr. Achim explore a topic rarely discussed openly in the oncology world: the long, arduous journey of rebuilding trust in your body after it feels like it has completely betrayed you. Dr. Achim shares how shifting from anger to radical self-love and mastering the art of strict presence—learning to live purely in the current moment—became his ultimate armor against the paralyzing fear of cancer recurrence. Whether you are a patient looking for tools to manage treatment intervals, a male patient looking for permission to voice your fears, or a caregiver trying to balance medical advocacy with emotional support, this episode offers an essential roadmap for finding steady footing when your world is turned upside down.Chapter Codes:00:00 Grounding in the Present Moment00:44 Dr. Achim's Transition From Patient to Caregiver02:15 The Reality of Being a Cancer Care Partner06:46 Navigating Aggressive Lymphoma & CAR T-Cell Therapy09:57 Healing the Feeling of "Body Betrayal"13:49 Mind-Body Visualizations During the Treatment Time Gap15:36 Overcoming the Fear of Cancer Recurrence19:33 Mental Health Stigmas for Male Cancer Patients25:25 Life with No Evidence of Disease (NED)Key Takeaways from This Episode:The Caregiver Shift: Why true caregiving isn't about having all the answers or trying to "fix" the disease; it is about steady, radical presence and holding a hand through the confusion.The "Betrayal" of the Body:Understanding the mental shift required to stop treating your body like an enemy and realizing that it is still actively fighting for you.The Power of Visualizations:How Dr. Achim used a 5-day Carl Simonton method seminar to train his mind during the critical "time gap" between diagnosis and treatment.Connect with Manta Cares & Patient from Hell:Learn more about our mission: Manta Cares WebsiteDiscover your personal cancer roadmap: Patient from Hell Podcast HubSubscribe, rate, and review on Apple Podcasts, Spotify, and YouTube!Disclaimer: This podcast, show notes, and newsletter are for general informational purposes only and do not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. The use of information on this podcast or any materials linked from it is at the user's own risk. The opinions of the speakers are their own and do not represent the organizations they are affiliated with, nor do they reflect the opinions of Manta Cares Inc. or its sponsors.

"I knew the diagnosis, the prognosis, and the five-year survival rates. And for the first time, knowing more didn't help, it made it worse."In this powerful episode of The Patient From Hell, host Samira sits down with Dr. Achim Zinggrebe, a German physician and pharmaceutical oncology expert who found himself on the other side of the stethoscope. After years of treating cancer and developing oncology drugs, Dr. Achim discovered fist-sized lymph nodes on his own MRI, leading to a diagnosis of advanced lymphoma with a 1-to-2-year survival outlook.Dr. Achim shares a raw, clinical, and deeply personal look at the "curse of knowledge" that comes when a doctor becomes the patient. We dive into the "mirror moment" that changed his trajectory, the scientific proof behind integrative therapies like meditation, and why the current medical system often fails to address the "mind and soul" of the person behind the pathology.In this episode, we discuss:The surreal experience of reading your own terminal cancer scans.Why "Dr. Google" is a universal trap, even for medical experts.The transition from conventional oncology to an integrative "Body, Mind, and Soul" approach.The "Mirror Moment": How to start fighting for yourself instead of everyone else.Crucial advice for clinicians on empathy, silence, and treating the human, not just the lab results.Guest Bio:Dr. Achim Zinggrebe is a physician, cancer survivor, and family member of a cancer patient. He works at the intersection of medicine, lived experience, and human reality.Having seen cancer from all three perspectives, his work focuses on helping people find clarity, inner stability, and direction in a time that often feels uncertain. He is the author of Rise and Thrive Above Cancer and the Rise and Thrive Journal, and the creator of a structured pathway that supports people during and beyond treatment in a grounded and honest way.Dr. Achim Zinggrebe joins us from Southern Germany to share how he transformed a devastating prognosis into a mission to provide a "shortcut" for other patients through his upcoming book and advocacy.Chapter Codes00:00 - The MRI That Changed Everything00:44 - Introducing Dr. Achim: Physician, Survivor, & Caregiver02:02 - From Paramedic to Oncology: A Career Built on Helping04:01 - The Diagnosis: Advanced Lymphoma05:30 - Ignoring the Signs: Why We Put Ourselves Last06:07 - The Curse of Knowledge: Why Knowing the Survival Rates is a Burden08:04 - Seeking Hope in a 2-Year Prognosis10:49 - What Medical School Never Taught Me About Being a Patient12:37 - The Missing Piece in Oncology: Body, Mind, and Soul15:12 - The Mirror Moment: Redefining the Role of Medicine18:30 - Rebuilding Your Identity After a Diagnosis22:51 - The Science of Integrative Medicine & Meditation26:53 - Advice to Clinicians: Listen More, Talk Less28:47 - The System vs. The Human BeingSupport the Podcast:If you found this story inspiring, please Like, Subscribe, and hit the Notification Bell. Sharing these stories helps break the stigma surrounding lung cancer and provides a community for those in the fight.#LungCancer #PatientStories #DoubleLungTransplant #CancerAdvocacy #PatientFromHell #ManticareDisclaimer:This podcast, show notes, and newsletter are for general informational purposes only and do not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice; no doctor-patient relationship is formed. The use of information on this podcast or any materials linked from this blog is at the user's own risk. The opinions of the speakers are their own and do not represent the opinions of organizations they are affiliated with, nor do they reflect the opinions of Manta Cares Inc. or Manta Cares' sponsors.

Why are you still so tired? If you’ve finished treatment but your energy hasn't returned, you aren't alone. In this episode, host Samira sits down with Naturopathic Doctor and author Dr. Jessa Landmann to dive deep into the world of Integrative Oncology.We move past the "war" metaphors to discuss a concept Dr. Landmann calls "Respecting Cancer." We explore why cancer-related fatigue is fundamentally different from being "just tired" and look at evidence-based tools—from iron infusions to aromatherapy—that can help you feel like yourself again.Plus, we’re doing some serious myth-busting on the topics currently blowing up your social media feeds: sugar, high-dose Vitamin C, and the latest trends in antiparasitics.📘 GET THE BOOK:Grab Dr. Landmann’s new book on cancer-related fatigue at Wiley Publishing.Use Code: PFH20 for 20% off!TIMESTAMP CHAPTERS:00:00 - Introduction: Vitamin C Myths00:47 - Dr. Landman’s Journey: From High School to Naturopathy03:23 - Defining Integrative Oncology vs. Complementary Medicine05:29 - The Difference Between Palliative Care & Integrative Oncology07:30 - What exactly is Cancer-Related Fatigue?11:49 - Finding the Root Cause: Anemia, Thyroid, and Sleep16:38 - When Oral Supplements Aren't Enough: The Case for Iron IVs18:00 - Surprising Research: Aromatherapy & Tapping (EFT) for Pain20:03 - How to Spot "Fringe" Science vs. Evidence-Based Care24:55 - Myth-Busting: High Dose Vitamin C as an Alternative?26:36 - The Truth About Sugar, Insulin, and Recurrence29:07 - Alcohol and Cancer: What the Research Actually Says30:23 - The "Antiparasitic" Trend on Social Media32:06 - Why We Need to "Respect Cancer"33:48 - Where to Find the Book & Special Discount CodeSummary:"Just be thankful you're alive." For many cancer survivors, this sentiment from the medical community isn't enough when they are too exhausted to work, volunteer, or enjoy their hobbies. Host Samira welcomes Dr. Jessa Landmann, an expert in integrative oncology with 15 years of experience, to discuss the "pervasive and crushing" reality of cancer-related fatigue.In this episode, we cover:The "Marriage" of Medicine: How integrative oncology works alongside conventional treatments like chemo and radiation to improve quality of life.The Fatigue Framework: Why cancer-related fatigue isn’t fixed by a weekend of rest and how to identify correctable causes like iron deficiency or sleep apnea.Evidence-Based "Woo": Dr. Landman shares the surprising clinical data behind aromatherapy and Tapping (EFT).Hard Truths: A no-nonsense look at sugar, alcohol, and the dangers of following "cancer influencers" over peer-reviewed research.Guest Bio:Dr. Jessa Landmann is a Naturopathic Doctor specializing in integrative oncology. With nearly 15 years in clinical practice, Dr. Landmann’s work is rooted in the belief that quality of life is just as important as the treatment itself. Her path was inspired by her mother’s 30-year cancer survivorship journey, leading her to write her latest self-help book focused on helping patients navigate and overcome cancer-related exhaustion.Special Offer:Dr. Landmann is offering The Patient From Hell community a 20% discount on her new book through Wiley Publishing.